May 5, 2015 -
Patient management solutions firm AMC Health will demonstrate its biometric-enabled monitored care technologies at the upcoming ATA 2015 Conference, held this week at the Los Angeles Convention Center.
AMC Health will discuss how its programs, solutions and services enhance monitored care to improve overall healthcare delivery, as well as deliver a joint presentation with Geisinger Health Plan on May 5th from 11 a.m. to 12 p.m.
The session, “Using IVR and Telemonitoring to Lower Hospital Admissions, Readmissions and Costs for Heart Failure (HF) Patients”, will share the results of a study that measured the impact of adding Bluetooth-enabled biometric telemonitoring and symptom/behavioral data capture via Interactive Voice Response (IVR) to GHP’s case management program for members previously diagnosed with HF.
The peer-reviewed study is based on the feedback of 541 patients, who participated in the program for an average of two years. The study is the first to accurately state dollar savings in clear terms and with a large population over a two year period.
Published in Population Health Management (Dec 2014), the study’s results include patients participating in the program experiencing a 23% lower probability of ending up in the hospital, hospitalized patients seeing a 44% reduced probability of re-hospitalization within 30 days, overall costs for patients in the program were 11.3% lower than the control group, and net savings of nearly $2.7 million over two years for 541 patients translated to a 3.3-to-1 program ROI.
The telehealth program, when combined with heart failure case management operations that are not as advanced as Geisinger’s, would deliver even higher ROIs, according to experts.
The presentation will provide attendees with a better understanding of the necessary processes, tools, training, resources and personnel to implement the program.
AMC Health solutions have been proven to lower all-cause hospital readmissions by 20 percent, reduce costs of care for patients with heart failure by 11 percent, improve HbA1c levels for patients with diabetes by 1.8 points, and improve blood pressure levels for patients with hypertension by 11/6 mmHg.